covidien plc (COV) Key Developments
Covidien plc Announces U.S. Food and Drug Administration 510(K) Clearance for the Kangaroo(TM) Feeding Tube with IRIS Technology
Apr 14 14
Covidien plc announced U.S. Food and Drug Administration 510(k) Clearance for the Kangaroo(TM) feeding tube with IRIS Technology. This camera-equipped disposable feeding tube is designed to enhance patient safety by providing visualization for a procedure that is currently blinded. The Covidien Integrated Real-time Imaging System (IRIS) technology streams a real-time video back to the Kangaroo IRIS monitor, providing visual information that can aid clinicians in identifying key areas of a patient's anatomy. The Covidien Integrated Real-time Imaging System (IRIS) technology streams a real-time video back to the Kangaroo IRIS monitor, providing visual information that can aid clinicians in identifying key areas of a patient's anatomy. The system also enables medical professionals to save images from the live stream and make notes associated with the image. Prior to availability of the Kangaroo feeding tube with IRIS technology, feeding tube placement was often done blindly. The risk associated with blind placement is the misplacement of the feeding tube into the patient's airway, which can potentially cause a punctured lung or even death. The Kangaroo feeding tube with IRIS technology now gives sight where medical professionals were previously blind. In addition to FDA clearance in the U.S., the Kangaroo feeding tube with IRIS technology is approved for use in Europe, Japan, Canada and Australia. The Kangaroo IRIS monitor is currently programmed with seven languages: English, Spanish, French, German, Italian, Portuguese and Dutch.
Covidien plc Declares Quarterly Cash Dividend, Payable on May 5, 2014
Mar 19 14
Covidien plc has declared a quarterly cash dividend of $0.32 per ordinary share. The dividend is payable on May 5, 2014, to shareholders of record on April 7, 2014.
Covidien plc Presents at Boston Biotech BD Boston Conference, Mar-25-2014 12:30 PM
Mar 14 14
Covidien plc Presents at Boston Biotech BD Boston Conference, Mar-25-2014 12:30 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: James C. Clemmer, Senior Vice President and President of Medical Supplies.
Covidien plc Launches Symbotex(TM) Composite Mesh for Surgical Laparoscopic and Open Ventral Hernia Repair
Mar 13 14
Covidien plc announced the U.S. launch of Symbotex(TM) composite mesh, an innovative product designed to make it easier for surgeons to perform surgical laparoscopic and open ventral hernia repairs. Symbotex(TM) composite mesh for surgical laparoscopic and open ventral hernia repair is designed to offer patients optimal hernia repair performance. A ventral hernia can develop when the outer layers of the abdominal wall weaken, bulge or tear, with most hernias resulting from strain on the abdominal muscles. Hernias can grow larger over time and cause serious complications if not surgically repaired. Comprising a macroporous monofilament, hydrophilic textile in a three-dimensional construction that allows for reinforced strength, memory shape and significant tissue ingrowth. A bioabsorbable collagen film on the visceral side minimizes tissue attachments. Symbotex mesh offers surgeons improved ease of use with an orientation marker that facilitates correctly placing the mesh over the hernia defect. Additionally, Symbotex mesh is transparent, offering improvements to the visualization of the anatomy during mesh placement and fixation. Symbotex composite mesh is available in a variety of shapes and sizes for laparoscopic and open ventral hernia repair.
Covidien plc Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-13-2014 10:45 AM
Feb 27 14
Covidien plc Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-13-2014 10:45 AM. Venue: Loews Miami Beach Hotel, Miami, Florida, United States. Speakers: Charles J. Dockendorff, Chief Financial Officer and Executive Vice President.